Caris Life Sciences, Inc. (CAI) Earnings History
Annual and quarterly earnings data from 2003 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | 5.6% | -66.2% |
| 2024 | 43.4% | -62.4% | -68.4% |
| 2023 | 29.2% | -104.4% | -111.5% |
| 2022 | 31.0% | -122.2% | -124.1% |
| 2020 | 62.6% | 47.3% | 9.4% |
Download Data
Export CAI earnings history in CSV or JSON format
Free sign-in required to download data
Caris Life Sciences, Inc. (CAI) Earnings Overview
As of March 5, 2026, Caris Life Sciences, Inc. (CAI) reported trailing twelve-month net income of -$538M, reflecting -0.2% year-over-year growth. The company earned $-0.32 per diluted share over the past four quarters, with a net profit margin of -0.7%.
Looking at the long-term picture, CAI's historical earnings data spans multiple years. The company achieved its highest annual net income of $79M in fiscal 2018.
Caris Life Sciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including VCYT ($66M net income, 0.1% margin), ADPT (-$80M net income, -0.9% margin), NAUT (-$63M net income), CAI has room to improve margins relative to the peer group. Compare CAI vs VCYT →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$538M | -90.8% | $45M | $-3.22 | -66.2% | 5.6% |
| 2024 | -$282M | +17.4% | -$257M | $-2.70 | -68.4% | -62.4% |
| 2023 | -$341M | -6.4% | -$320M | $-1.82 | -111.5% | -104.4% |
| 2022 | -$321M | -1256.8% | -$316M | $-1.57 | -124.1% | -122.2% |
| 2020 | $28M | -10.6% | $139M | $1.55 | 9.4% | 47.3% |
| 2019 | $31M | -60.5% | $130M | $1.72 | 7.4% | 31.3% |
| 2018 | $79M | +9.1% | $149M | $3.97 | 18.2% | 34.4% |
| 2017 | $72M | +1101.6% | $106M | $3.68 | 20.7% | 30.3% |
| 2016 | $6M | -77.7% | $66M | $0.31 | 2.0% | 22.4% |
| 2015 | $27M | -55.5% | $68M | $1.28 | 10.7% | 27.3% |
See CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CAI vs LLY
See how CAI stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is CAI growing earnings?
CAI EPS of $-0.32 reflects slowing growth at -0.2%, below the 5-year CAGR of N/A. TTM net income is $-538M. Expansion rate has moderated.
What are CAI's profit margins?
Caris Life Sciences, Inc. net margin is -0.7%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are CAI's earnings?
CAI earnings data spans 2003-2025. The current earnings trend is -0.2% YoY. Historical data enables comparison across business cycles.